The Revised Criteria of Alzheimer's Association Workgroup supported the use of plasma p‐tau isoforms for the diagnosis of AD, thus suggesting migrating from more invasive and expensive assays to a more accessible tool [8]. This evidence concerns the gene MAPT and Alzheimer disease.